Chapter 33

Introduction

  • Gifts from drug companies to physicians were once very common.

  • A 2001 study indicated that 97% of residents had at least one branded item (e.g., reference books, pens, information cards).

  • Concerns about conflicts of interest have led to a decline in such gifts.

  • This chapter discusses arguments for and against accepting these gifts and provides guidelines.

Types of Gifts

  • In 2012, pharmaceutical manufacturers spent over $15 billion on drug detailing to US physicians and nearly $6 billion on drug samples, averaging around $26,000 per physician.

  • Total promotional spending was almost double that of research and development costs.

Continuing Medical Education (CME)

  • Drug companies invest over $2 billion annually in educational and promotional meetings.

  • More than 60% of CME funding now comes from commercial sources, including the pharmaceutical sector.

  • CME programs must disclose drug company payments and review for potential bias.

  • Company-sponsored CME programs often focus less on prevention and lifestyle compared to academic-sponsored programs.

Meals and Hospitality

  • Drug companies provide food at hospital conferences or CME events to boost attendance.

  • Pharmaceutical representatives often pay for meals for physicians and their staff.

Drug Detailing

  • Pharmaceutical representatives offer tailored information and gifts, along with free drug samples.

  • Studies show that exposure to drug company information correlates with increased prescriptions and higher costs.

  • Representatives create prescribing profiles and utilize strategies to connect with physicians.

Reasons for Drug Companies to Offer Gifts

  • Gifts can enhance physicians' product recognition and influence prescribing behavior, leading to an increased likelihood of prescribing sponsor medications.

  • Physicians who accept gifts often do not believe those gifts influence their decisions.

Reasons for Accepting Drug-Company Gifts

  • Some argue that gifts can subsidize medical education and improve attendance at professional events.

  • Drug samples are seen as providing access to medications for underserved populations; however, this may be less beneficial than perceived.

Objections to Accepting Drug-Company Gifts

  • Gift Impact: Impaired Objectivity

    • Gifts can compromise objectivity in medical presentations.

    • Speaker presentations may not disclose all adverse information.

  • Trust Issues

    • Gifts can undermine patient trust and may influence public perception negatively.

  • Perception of Professionalism

    • Dependence on drug company gifts can devalue the medical profession in the public's eyes.

  • Reciprocity Expectations

    • Gifts foster expectations of reciprocation and can lead to biased prescribing.

  • Healthcare Costs

    • Patients effectively pay for the gifts, contributing to the overall rise in healthcare costs.

Recommendations

  • Transparency

    • Physicians must disclose received gifts in CME program syllabi.

    • Under the Physician Payment Sunshine Act, companies must report substantial payments to physicians.

  • Boundaries for Acceptable Gifts

    • Certain supports (e.g., grants for CME) are acceptable with disclosure, provided there is no influence on content.

  • Forbidding Harmful Practices

    • Restrictions should be placed on gifts that have a high potential for bias or impropriety.

    • Recognized organizations suggest avoiding direct payments for participation in non-educational activities.

Summary

  • Acceptance of gifts from drug companies can impair objectivity and undermine public trust while increasing healthcare costs.

  • The principal focus of physicians should be on their patients' interests.